Skip to main content
Log in

Effects of Proteolytic Enzyme Inhibitors on the Nasal Absorption of Vasopressin and an Analogue

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Proteolytic enzyme inhibitors were examined as absorption enhancers for the nasal delivery of vasopressin (AVP) and desmopressin (l-d-8-DAVP) in rats. Aprotinin, soybean trypsin inhibitor, and camostat mesilate were used as enzyme inhibitors. The nasal absorption of AVP and l-d-8-DAVP was evaluated by measuring its antidiuretic effect. Nasal administration of AVP (0.005 IU/kg) or l-d-8-DAVP alone (2.5 ng/kg) produced a small antidiuretic effect. Coadministration with aprotinin (1000 and 10000 KIU/kg) or soybean trypsin inhibitor (1.25 and 6.25 mM) did not change the antidiuretic effect. However, coadministration with camostat mesilate (1 to 50 mM) significantly increased the antidiuretic effect and, thus, the nasal absorption of AVP and l-d-8-DAVP. The activities of aminopeptidase, cathepsin-B, and trypsin in the nasal mucosal tissue of rats were 7 nmol/min/mg protein, 0.7 nmol/min/mg protein, and 4.6 pmol/min/mg protein, respectively. Aprotinin and soybean trypsin inhibitor inhibited only the trypsin activity, whereas camostat mesilate inhibited aminopeptidase and trypsin activities. Aprotinin (MW 6500) and soybean trypsin inhibitor (MW 8000), with relatively high molecular weights, may not permeate into the nasal mucosal tissue. In contrast, camostat mesilate is slowly absorbed (8%/hr) and could inhibit the proteolytic activity in the nasal mucosa, resulting in enhanced nasal absoprtion of AVP and l-d-8-DAVP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. Y. W. Chien, K. S. E. Su, and S. F. Chang (eds.). Nasal Systemic Drug Delivery, Marcel Dekker, New York, 1989, pp. 1–26.

    Google Scholar 

  2. C. McMartin, L. E. F. Hutchinson, R. Hyde, and D. E. Peters. Analysis of structural requirements for the absorption of drugs and macromolecule from the nasal cavity. J. Pharm. Sci. 76:535–540 (1987).

    Google Scholar 

  3. V. H. L. Lee. Enzymatic barriers to peptide and protein absorption and use of penetration enhancer to modify absorption. In S. S. Davis, L. Ilium, and E. Tomlinson (eds.), Delivery Systems for Peptides Drugs, Plenum Press, New York, 1986, pp. 87–104.

    Google Scholar 

  4. I. Vavara, A. Machova, and I. Krejci. Antidiuretic action of l-deamino-8-D-arginine-vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 188:241–247 (1987).

    Google Scholar 

  5. J. M. M. van Bree, S. Tio, A. G. de Boer, M. Danhof, J. C. Verhoef, and D. D. Breimer. Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology. Pharm. Res. 7:293–298 (1990).

    Google Scholar 

  6. K. Morimoto, H. Yamaguchi, Y. Iwakura, K. Morisaka, Y. Ohashi, and Y. Nakai. Effects of viscous hyaluronate-sodium solution on the nasal absorption of vasopressin and an analogue. Pharm. Res. 8:471–474 (1991).

    Google Scholar 

  7. S. Koyama, M. Sasaki, T. Setoyama, K. Takahashi, K. Togashi, K. Suzuki, N. Nakai, and M. Imai. Dopaminergic modulation of the renal effect of arginine-vasopressin in waterloaded rats. Jpn. J. Pharmacol. 38:25–30 (1985).

    Google Scholar 

  8. S. Hirai, T. Yashiki, T. Matsuzawa, and H. Mima. Absorption of drugs from the nasal mucosa of rat. Int. J. Pharm. 7:317–325 (1981).

    Google Scholar 

  9. Y. Ohashi and Y. Nakai. Reduced ciliary action in chronic sinusitis. Acta Otolaryngol. Suppl. 397:3–9 (1983).

    Google Scholar 

  10. F. Komada, K. Okumura, and R. Hori. Fate of porcine and human insulin at the subcutaneous injection site. II. In vitro degradation of insulins in the subcutaneous tissue of the rat. J. Pharmacobio-Dyn. 8:33–40 (1985).

    Google Scholar 

  11. K. Morimoto, T. Iwamoto, and K. Morisaka. Possible mechanism for the enhancement of rectal absorption of hydrophilic drugs and polypeptides by aqueous polyacrylic acid gel. J. Pharmacobio-Dyn. 10:85–91 (1987).

    Google Scholar 

  12. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4:879–885 (1985).

    Google Scholar 

  13. M. A. Hussain, A. B. Shenvi, and S. M. Rowe, and E. Shefter. The use of α-aminoboronic acid derivatives to stabilize peptide drugs during their intranasal absorption. Pharm. Res. 6:186–189 (1989).

    Google Scholar 

  14. M. Saffran, C. Bedra, G. S. Kumar, and D. C. Nackers. Vasopressin: A model for the study of effects of additives on the oral and rectal administration of peptide drugs. J. Pharm. Sci. 77:33–38 (1988).

    Google Scholar 

  15. T. Owaki, H. Ando, F. Kakimoto, K. Uesugi, S. Watanabe, Y. Miyake, and M. Kayano. Effects of dose, pH and osmolarity on nasal absorption of secretion in rats. II. Histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity. J. Pharm. Sci. 76:695–698 (1987).

    Google Scholar 

  16. W. A. J. J. Hermans and F. W. H. Merkus. The influence of drugs on nasal ciliary movement. Pharm. Res. 4:445–449 (1987).

    Google Scholar 

  17. W. A. J. J. Hermans, P. M. Hooymans, C. Verhoef, and F. W. H. Merkus. Effects of absorption enhancers on the human nasal tissue ciliary movement in vitro. Pharm. Res. 7:144–146 (1990).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morimoto, K., Yamaguchi, H., Iwakura, Y. et al. Effects of Proteolytic Enzyme Inhibitors on the Nasal Absorption of Vasopressin and an Analogue. Pharm Res 8, 1175–1179 (1991). https://doi.org/10.1023/A:1015862603939

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015862603939

Navigation